Enalare Therapeutics Snags BARDA Contract for Intramuscular ENA-001

Enalare Therapeutics has secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $50.3 million for its investigational respiratory stimulant ENA-001.

The contract from the HHS agency is focused on developing ENA-001 in an intramuscular formulation for treatment for patients experiencing drug overdose. It may also be used as a medical countermeasure for mass casualty events.

The award will fund pre-clinical toxicology, human clinical studies, drug and device manufacturing and regulatory submission for a formulation of ENA-001 suitable for community use, the company said.

Enalare said it intends to start additional clinical trials with ENA-001 for several indications “in the near term.”